Evidence map›Paper›PMID 38592665›Full record

ArticleDrug safety2024

Lessons Learned on Observed-to-Expected Analysis Using Spontaneous Reports During Mass Vaccination.

María Gordillo-Marañón, Gianmario Candore, Karin Hedenmalm, Kate Browne, Robert Flynn, Loris Piccolo, Aniello Santoro, Cosimo Zaccaria, Xavier Kurz

Abstract read
In one paragraph

Article in Drug safety, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

María Gordillo-MarañónData Analytics and Methods Task Force, European Medicines Agency, Amsterdam, The Netherlands. maria.maranon.16@ucl.ac.uk.ORCID http://orcid.org/0000-0003-2993-6577
Gianmario CandoreMedical Affairs and Pharmacovigilance, Pharmaceuticals, Bayer AG, Berlin, Germany.
Karin HedenmalmData Analytics and Methods Task Force, European Medicines Agency, Amsterdam, The Netherlands.
Kate BrowneStakeholders and Communication, European Medicines Agency, Amsterdam, The Netherlands.
Robert FlynnData Analytics and Methods Task Force, European Medicines Agency, Amsterdam, The Netherlands.
Loris PiccoloData Analytics and Methods Task Force, European Medicines Agency, Amsterdam, The Netherlands.
Aniello SantoroPharmacovigilance Office, European Medicines Agency, Amsterdam, The Netherlands.
Cosimo ZaccariaPharmacovigilance Office, European Medicines Agency, Amsterdam, The Netherlands.
Xavier KurzData Analytics and Methods Task Force, European Medicines Agency, Amsterdam, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During the COVID-19 vaccination campaign, observed-to-expected analysis was used by the European Medicines Agency to contextualise data from spontaneous reports to generate real-time evidence on emerging safety concerns that may impact the benefit-risk profile of COVID-19 vaccines. Observed-to-expected analysis compares the number of cases spontaneously reported for an event of interest after vaccination ('observed') to the 'expected' number of cases anticipated to occur in the same number of individuals had they not been vaccinated. Observed-to-expected analysis is a robust methodology that relies on several assumptions that have been described in regulatory guidelines and scientific literature. The use of observed-to-expected analysis to support the safety monitoring of COVID-19 vaccines has provided valuable insights and lessons on its design and interpretability, which could prove to be beneficial in future analyses. When undertaking an observed-to-expected analysis within the context of safety monitoring, several aspects need attention. In particular, we emphasise the importance of stratified and harmonised data collection both for vaccine exposure and spontaneous reporting data, the need for alignment between coding dictionaries and the crucial role of accurate background incidence rates for adverse events of special interest. While these considerations and recommendations were determined in the context of the COVID-19 mass vaccination setting, they are generalisable in principle.

Indexed as

COVID-19COVID-19 VaccinesMass VaccinationAdverse Drug Reaction Reporting SystemsHumansSARS-CoV-2COVID-19 Vaccines

Identifiers

PMID38592665
PMCPMC11182835

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.